Boston, MA -- (ReleaseWire) -- 01/16/2015 --The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer vaccine partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer vaccine partnering contract documents
Top cancer vaccine deals by value

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

View Full Report Details and Table of Contents

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 160 links to online copies of actual cancer vaccine deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of cancer vaccine dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer vaccine dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms by stage of development.It also provides the number of deals entered by top 50 big pharma, big biotech and most active dealmakers in cancer vaccine partnering.

Chapter 3 provides a review of the leading cancer vaccine deals since 2009. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive and detailed review of all cancer vaccine partnering deals signed and announced since January 2009.The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes adjuvant deals and alliances.

The report also includes numerous tables and figures that illustrate the trends and activities in cancer vaccine partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer vaccine technologies and products.

Report scope

Cancer Vaccine Partnering Agreements is intended to provide the reader with an in-depth understanding and access to cancer vaccine trends and structure of deals entered into by leading companies worldwide.

Cancer Vaccine Partnering Agreements includes:

- Trends in cancer vaccine dealmaking in the biopharma industry since 2009
- Analysis of cancer vaccine deal structure
- Access to headline, upfront, milestone and royalty data
- Access to over 160 cancer vaccine deal records
- The leading cancer vaccine deals by value since 2009
- Includes adjuvant and drug delivery deals and alliances since 2009

In Cancer Vaccine Partnering Agreements, the available deals are listed by:

- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific oncology therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Cancer Vaccine Partnering Agreements report provides comprehensive access to available deals and contract documents for over 160 cancer vaccine deals. Analyzing actual contract agreements allows assessment of the following:

Companies Mentioned in this Report: A*STAR Bioprocessing Technology Institute, Adamis Pharmaceuticals, Adjuvantix, AdnaGen, Aduro BioTech, Advaxis, Affitech, Agenus Bio, Agilent Technologies, Aldevron, Alexis Biotech, Alnylam Pharmaceuticals, AnGes MG, Antigen Express, Antigenics, Argos Therapeutics, Ariad Pharmaceuticals, Asterias Biotherapeutics, AstraZeneca, Astrimmune, AV Therapeutics, Averion, Batu Biologics, Bavarian Nordic, Bayer Innovation, Baylor College, Baylor College of Medicine, Baylor Research Institute, Beijing Genomics Institute (BGI), Bellicum Pharmaceuticals, Beth Israel Deaconess Medical Center, BinnoPharm, Bio-Matrix Scientific, BioAlliance Pharma, BioClones, Biooutsource, BioSante Pharmaceuticals, BioTime, BioVest, BioWa, Bristol-Myers Squibb, Broadvector, Brown University, Cadila Pharmaceuticals, Cancer Prevention and Research Institute of Texas, Cancer Research Institute, Cancer Research Technology, Cancer Research UK, Cancer Research Wales, Cardiff University, Catherex, Cedars-Sinai Medical Center, Champions Oncology, ChemRar High-Tech Center, City of Hope, Cleveland BioLabs, Clinigen, Clinipace Worldwide, Cobra Biologics, Colby Pharmaceuticals, CSIRO, CSL, CureLab Oncology, CureVac, Daiichi Sankyo, Dalton Pharma Services, Dana-Farber Cancer Institute, DanDrit Biotech, Davospharma, DCPrime, Delta-Vir, Dendreon, Department of Defense, Diosynth, Dynavax Technologies, Encorium Group, Entest BioMedical, Etubics, European Union, Federal Ministry of Education and Research (BMBF), Formatech, Forska and Vax, Fraunhofer Institute for Cell Therapy and Immunology, Fred Hutchinson Cancer Research Center, G-Con, Galena Biopharma, Genentech, Generex Biotechnology, Genetic Immunity, GenoLac, Genomic Expression, German Cancer Research Center, GlaxoSmithKline, Gradalis, Gynecologic Oncology Group, Heat Biologics, HemaCare, HemispheRx Biopharma, Hokkaido University, IBio, Icahn School of Medicine at Mount Sinai, Ichor Medical Systems, Immatics Biotechnologies, Immune Design, ImmuneRegen BioSciences, Immunicum, ImmunoCellular Therapeutics, Immunomedics, Immunotope, Immunovaccine, ImmunoVaccine Technologies, Immunovo, Inovio Pharmaceuticals, InteRNA Technologies, IRX Therapeutics, ISSI-Strategy, Jaiva Technologies, Janssen Pharmaceuticals, Jantibody Therapeutics, Japan Vaccine, Jennerex, John Hopkins University School of Medicines, Johns Hopkins University, JSC Binnopharm, Juvaris BioTherapeutics, KAEL-GemVax, KellBenx, Kirin Pharma, Kyowa Hakko Kirin, Leukaemia & Lymphoma Research, Ligand Pharmaceuticals, Lipoxen, London Genetics, Ludwig Institute for Cancer Research, LUNGevity Foundation, MabVax Therapeutics, Madison Vaccines, Mary Crowley Cancer Research Center, Mayo Clinic, MD Anderson Cancer Center, Medarex, MediGene, MedImmune, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck KGaA, Merck Serono, Merix Bioscience, Methodist Hospital Research Institute, Ministry of Industry and Trade of the Russian Federation, MorphoSys, Morphotek, Nanobiotix, National Cancer Institute, National Cancer Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health, National Research Council Canada, NeoStem, NewVac, Northwest Biotherapeutics, Norwegian Cancer Society, Norwegian Research Council, Nottingham City Council, Novartis, Novavax, Numoda, NYU Langone Medical Center, Ohio State University, Omnimmune, OncoPep, OncoSec Medical, Oncotherapy Science, Oncothyreon, Oncovir, Ono Pharmaceutical, Opsona Therapeutics, Oxford BioMedica, Oxford Immunotec, Panacela Labs, Pepscan Therapeutics, Pfenex, Pfizer, Pharmsynthez, Pique Therapeutics, PPD, Pro-Cure Therapeutics, Progenitor Cell Therapy, Prometheus Laboratories, Prostate Cancer Foundation (PCF), PsiOxus Therapeutics, Pulmotec, Qiagen, Radboud University Nijmegen Medical Centre, Radiation Control Technologies, Radient Pharmaceuticals, Regen BioPharma, Roche, Rosetta Genomics, RXi Pharmaceuticals, San Martino Hospital, Scancell, Sellas Clinicals Holding, SFJ Pharmaceuticals, SOTIO, Spectrum Pharmaceuticals, Stellar Biotechnologies, Stellar Pharmaceuticals, Stemline Therapeutics, Symphony Dynamo, TapImmune, Tasly Pharmaceuticals, Technomark Life Sciences, Teva Pharmaceutical Industries, The Regents of the University of California, Therinject, ToleRx, Torrey Pines Institute for Molecular Studies, Transgene, Transgene Tasly Biopharmaceutical, UK Government, University of California, Davis, University of California, San Diego, University of Connecticut, University of Copenhagen, University of Miami, University of Pennsylvania, University of Pennsylvania School of Veterinary Medicine, University of Pittsburgh, University of Queensland, University of Rouen, University of Western Ontario, Vaccibody, Vaccinogen, Vanderbilt University, Vaxil BioTherapeutics, Vaximm, Vinnova, ViroMed, Vivalis, VLST Corporation, VU University Amsterdam, Wilex, Wistar Institute, Xencor

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 800-844-8156

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Cancer Diagnostics Partnering Terms and Agreements
- Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
- Pharmacogenomics Partnering Terms and Agreements
- Gene Therapy Partnering Terms and Agreements
- Cervical Cancer Partnering 2009-2014